Nkarta (NKTX) vs Atrium Therapeutics (RNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Atrium Therapeutics is the larger company by market cap ($131.2 million vs $128.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NKTX | RNA |
|---|---|---|
| Share price | $1.80 | $7.67 |
| Market cap | $128.92M | $131.20M |
| 1-day change | -6.74% | -1.92% |
| YTD return | -2.70% | — |
| 1-year return | -21.74% | — |
| 5-year return | -89.49% | — |
| EPS (TTM) | $-1.58 | $-5.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-104.08M | — |
| 52-week high | $3.72 | $16.77 |
| 52-week low | $1.70 | $7.54 |
| Distance from 52-week high | -51.61% | -54.26% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +501.67% | +225.95% |
| Average volume | 641.25K | 259.72K |
| Shares outstanding | 71.62M | 17.11M |
| Employees | 106 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
NKTX vs RNA FAQ
Which is bigger, Nkarta or Atrium Therapeutics?
Atrium Therapeutics (RNA) is larger, with a market capitalization of $131.20M compared with $128.92M for Nkarta (NKTX).
Are Nkarta and Atrium Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.